| # | Title | Journal | Year | Citations |
|---|
| 1 | Determination of subcutaneous tumor size in athymic (nude) mice | Cancer Chemotherapy and Pharmacology | 1989 | 1,484 |
| 2 | Platinum-based drugs: past, present and future | Cancer Chemotherapy and Pharmacology | 2016 | 646 |
| 3 | Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients | Cancer Chemotherapy and Pharmacology | 2000 | 623 |
| 4 | Matrix metalloproteinases and metastasis | Cancer Chemotherapy and Pharmacology | 1999 | 621 |
| 5 | Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent | Cancer Chemotherapy and Pharmacology | 1995 | 488 |
| 6 | The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin | Cancer Chemotherapy and Pharmacology | 1998 | 471 |
| 7 | Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II | Cancer Chemotherapy and Pharmacology | 1982 | 470 |
| 8 | Multidrug resistance: molecular mechanisms and clinical relevance | Cancer Chemotherapy and Pharmacology | 1997 | 470 |
| 9 | Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats | Cancer Chemotherapy and Pharmacology | 2011 | 441 |
| 10 | Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis | Cancer Chemotherapy and Pharmacology | 2010 | 428 |
| 11 | Ruthenium-based chemotherapeutics: are they ready for prime time? | Cancer Chemotherapy and Pharmacology | 2010 | 421 |
| 12 | Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models | Cancer Chemotherapy and Pharmacology | 2007 | 419 |
| 13 | Cancer and the tumor microenvironment: a review of an essential relationship | Cancer Chemotherapy and Pharmacology | 2009 | 403 |
| 14 | Advances in ovarian cancer therapy | Cancer Chemotherapy and Pharmacology | 2018 | 393 |
| 15 | Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation | Cancer Chemotherapy and Pharmacology | 1989 | 387 |
| 16 | Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine | Cancer Chemotherapy and Pharmacology | 2013 | 368 |
| 17 | Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway | Cancer Chemotherapy and Pharmacology | 2013 | 367 |
| 18 | A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors | Cancer Chemotherapy and Pharmacology | 2013 | 362 |
| 19 | The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review | Cancer Chemotherapy and Pharmacology | 1999 | 351 |
| 20 | A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer | Cancer Chemotherapy and Pharmacology | 2011 | 350 |
| 21 | Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity | Cancer Chemotherapy and Pharmacology | 2004 | 345 |
| 22 | Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors | Cancer Chemotherapy and Pharmacology | 1995 | 331 |
| 23 | Clinical pharmacokinetics of bevacizumab in patients with solid tumors | Cancer Chemotherapy and Pharmacology | 2008 | 317 |
| 24 | Phase I study of oxaliplatin in patients with advanced cancer | Cancer Chemotherapy and Pharmacology | 1990 | 311 |
| 25 | Successful management of microscopic residual disease in large bowel cancer | Cancer Chemotherapy and Pharmacology | 1999 | 310 |
| 26 | Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine | Cancer Chemotherapy and Pharmacology | 2007 | 297 |
| 27 | The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy | Cancer Chemotherapy and Pharmacology | 2016 | 297 |
| 28 | Failure to preserve fertility in patients with Hodgkin's disease | Cancer Chemotherapy and Pharmacology | 1987 | 290 |
| 29 | In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng | Cancer Chemotherapy and Pharmacology | 2007 | 280 |
| 30 | Role of mitochondria as the gardens of cell death | Cancer Chemotherapy and Pharmacology | 2006 | 278 |
| 31 | Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer | Cancer Chemotherapy and Pharmacology | 1978 | 273 |
| 32 | A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells | Cancer Chemotherapy and Pharmacology | 2010 | 272 |
| 33 | Rapid chemosensitivity testing of human lung tumor cells using the MTT assay | Cancer Chemotherapy and Pharmacology | 1986 | 262 |
| 34 | A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer | Cancer Chemotherapy and Pharmacology | 2009 | 261 |
| 35 | Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen | Cancer Chemotherapy and Pharmacology | 2005 | 260 |
| 36 | Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer | Cancer Chemotherapy and Pharmacology | 2012 | 257 |
| 37 | Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice | Cancer Chemotherapy and Pharmacology | 1999 | 254 |
| 38 | Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein | Cancer Chemotherapy and Pharmacology | 1997 | 250 |
| 39 | Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines | Cancer Chemotherapy and Pharmacology | 1993 | 249 |
| 40 | Current status of the molecular mechanisms of anticancer drug-induced apoptosis | Cancer Chemotherapy and Pharmacology | 2002 | 243 |
| 41 | Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target | Cancer Chemotherapy and Pharmacology | 1994 | 242 |
| 42 | Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center | Cancer Chemotherapy and Pharmacology | 1997 | 242 |
| 43 | Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial | Cancer Chemotherapy and Pharmacology | 2013 | 239 |
| 44 | Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine | Cancer Chemotherapy and Pharmacology | 1991 | 235 |
| 45 | Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer | Cancer Chemotherapy and Pharmacology | 2005 | 230 |
| 46 | Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer | Cancer Chemotherapy and Pharmacology | 2012 | 230 |
| 47 | Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene | Cancer Chemotherapy and Pharmacology | 2006 | 229 |
| 48 | Phase II trial of titanocene dichloride in advanced renal-cell carcinoma | Cancer Chemotherapy and Pharmacology | 1998 | 228 |
| 49 | Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care | Cancer Chemotherapy and Pharmacology | 2008 | 228 |
| 50 | Cisplatin nephrotoxicity | Cancer Chemotherapy and Pharmacology | 1989 | 225 |
